GMEDNYSESurgical & Medical Instruments & ApparatusUS GAAP · USD

Globus Medical, Inc

Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures. It combines implantable devices, biologics, surgical instruments and enabling technologies such as robotics and navigation to help surgeons perform procedures more efficiently and reproducibly.

Kysy yhtiöstä
Liikevaihto2 939milj. USD
+16,7 %v/v
Liikevoitto (EBIT)480milj. USD
+189,1 %v/v
EBIT-marginaali16,3%
+9,7 %-yks.v/v
Nettotulos538milj. USD
+422,3 %v/v
Vapaa kassavirta589milj. USD
+45,3 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

01 0002 0003 000milj. USD2020: 789 milj. USD2020: EBIT 111 milj. USD20202021: 958 milj. USD2021: EBIT 172 milj. USD20212022: 1 023 milj. USD2022: EBIT 228 milj. USD20222023: 1 568 milj. USD2023: EBIT 133 milj. USD20232024: 2 519 milj. USD2024: EBIT 166 milj. USD20242025: 2 939 milj. USD2025: EBIT 480 milj. USD20252 939480
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Globus Medical, Inc

Liiketoiminta

Osuus liikevaihdosta
Musculoskeletal Solutions85 %

Implantable devices, biologics, accessories, unique surgical instruments, neuromonitoring and stimulation products used in spine and orthopedic procedures.

Enabling Technologies15 %

Advanced hardware, software and related technologies that improve surgical precision, workflow and reproducibility.

Tuotteet

Raportoitu · osuus liikevaihdosta
95,2%FY2025100 %
  • Musculoskeletal Solutions95,2 %
  • Enabling Technologies4,8 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Globus sells primarily to hospitals, ambulatory surgery centers and physicians that perform musculoskeletal procedures and need both implants and the supporting surgical workflow tools. Its products are bought to improve surgical outcomes, reduce procedure complexity and support surgeon preference across a broad range of spine and orthopedic cases.

Hospitals

Buy implant sets, instruments, biologics and enabling technologies for inpatient and outpatient musculoskeletal procedures.

Ambulatory surgery centers

Buy procedure-ready systems and technologies that support faster, more efficient outpatient surgery.

Physicians and surgeons

Influence product selection and buy or specify surgeon-preferred implants, tools and navigation systems.

International distributors

Sell and support Globus products in non-U.S. markets where direct coverage is not used.

Strategia

Globus is focused on expanding its U.S. sales force, deepening penetration in existing territories and broadening coverage into new geographies. It is also pursuing international expansion and selective acquisitions to add technology, clinical capability and market access, while continuing to launch new products across its musculoskeletal portfolio.

Expand U.S. sales force and territory coverageLyhyt aikaväli

More reps and broader coverage should increase procedure adoption and deepen account penetration.

International expansionKeskipitkä aikaväli

Broader non-U.S. commercialization diversifies revenue and extends the installed base for products and technologies.

Selective acquisitions and alliancesKeskipitkä aikaväli

Acquisitions can add technology, personnel and market access that accelerate growth and product breadth.

Product innovation and launchesLyhyt aikaväli

Frequent launches support surgeon adoption and help defend share in a competitive device market.

Maantiede

Q1/2026

Globus is headquartered in Audubon, Pennsylvania and operates globally, with sales presence in 65 countries worldwide and direct or distributor coverage in 64 countries outside the U.S. The U.S. remains the largest market, but international growth matters because the company is still expanding its commercial footprint across Europe, the Middle East, Asia Pacific and Latin America.

USA80 %
Other countries (US filing)20 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Globus faces execution risk from integrating acquisitions, maintaining surgeon and hospital adoption, and managing a global supply chain that depends on third-party suppliers and international operations. It also faces regulatory, reimbursement, litigation and foreign-exchange risks typical of medical device companies, with tariff policy and customer credit exposure adding pressure to margins and cash flow.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Acquisition integration risk1Competitive adoption risk2Regulatory and compliance risk3Tariff and supply-chain disruption4Foreign exchange and international operations5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Acquisition integration riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company has grown through acquisitions and may not realize expected synergies or product benefits.

    KohdistuuNuVasiveNevroOther acquired businesses
  2. Competitive adoption riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Revenue depends on convincing surgeons and hospitals that Globus systems are preferable to alternatives.

    KohdistuuSpineOrthopedicNeurosurgical procedure markets
  3. Regulatory and compliance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Medical device marketing, manufacturing and biologics activities are subject to FDA and fraud-and-abuse rules.

    Kohdistuu: U.S. and foreign regulatory regimes

  4. Tariff and supply-chain disruptionVaikutus: KeskitasoTodennäköisyys: Korkea

    Tariffs or countermeasures can increase input costs and disrupt global sourcing and distribution.

    Kohdistuu: International supply chain and third-party suppliers

  5. Foreign exchange and international operationsVaikutus: KeskitasoTodennäköisyys: Korkea

    Non-U.S. revenue and costs create translation and transaction exposure.

    KohdistuuEuropeMiddle EastAsia PacificLatin America
Kysy Clarifolta: Globus Medical, Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Implants are recognized when used or control transfers, while services and support may be recognized over time.

Vaikutus: Can shift revenue between quarters and affect comparability

Goodwill and intangible impairment

Acquisitions create goodwill that must be tested annually or when indicators arise.

Vaikutus: Potential non-cash impairment charges

Acquisition accounting and bargain purchase gain

Recent acquisitions require fair value allocation of assets and liabilities, with possible bargain purchase gains.

Vaikutus: Can create volatile non-operating gains

Inventory and excess/obsolete reserves

Field inventory, consigned sets and surgical instruments require judgment on obsolescence and recoverability.

Vaikutus: Affects cost of sales and gross margin

Foreign currency translation

International operations generate gains and losses from currency movements.

Vaikutus: Can move other income/expense and net income

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Stryker Corporation

SYK · Surgical & Medical Instruments & Apparatus

Enovis CORP

ENOV · Orthopedic, Prosthetic & Surgical Appliances & Supplies

ENvue Medical, Inc.

FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Alphatec Holdings, Inc.

ATEC · Surgical & Medical Instruments & Apparatus

Medtronic plc

MDT · Electromedical & Electrotherapeutic Apparatus

Inspire Medical Systems, Inc.

INSP · Surgical & Medical Instruments & Apparatus

Päivitetty: 24.9.2026

Globus Medical, Inc (GMED) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo